FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2951542229> ?p ?o ?g. }

• W2951542229 endingPage "71" @default.
• W2951542229 startingPage "62" @default.
• W2951542229 abstract "Background Atopic dermatitis (AD) has a variable disease course and intermittent triggers, and responses to topical therapy vary, potentially affecting the magnitude of the placebo response in AD trials. Objective To determine the predictors of increased placebo response in randomized controlled trials of AD. Methods We performed a systematic review and meta-analysis of randomized controlled trials for systemic therapy in AD published during 2007-2018. We searched the Cochrane Library, Medline, Embase, Global Resource for EczemA Trials (GREAT), Literature of the Latin American and Caribbean Health Sciences (LILACS), and Scopus. Two authors performed study selection and data extraction. Multivariable mixed models were constructed for Cohen D of Eczema Area and Severity Index (EASI), SCORing Atopic Dermatitis (SCORAD), numeric rating scale (NRS)–itch and visual analog scale (VAS)–itch, and Dermatology Life Quality Index (DLQI). Results Overall, 64 trials were included. Use of concomitant topical therapy prescriptions, study duration ≥3 months, and fewer treatment arms were associated with an increased placebo response for EASI, NRS- and VAS-itch, and DLQI. For EASI, the placebo response was increased in studies with a higher proportion of male patients, mild-moderate mean baseline EASI scores, and no blinding. For NRS-itch, and VRS-itch, higher placebo responses were associated with higher proportions of male patients and moderate-severe mean itch scores at baseline. Conclusion Placebo responses can be reduced in clinical trials of systemic therapy in AD by incorporating double- and triple-blinding, balancing the sex distribution of patients, disallowing concomitant use of prescription topical therapy, and having shorter study durations. Atopic dermatitis (AD) has a variable disease course and intermittent triggers, and responses to topical therapy vary, potentially affecting the magnitude of the placebo response in AD trials. To determine the predictors of increased placebo response in randomized controlled trials of AD. We performed a systematic review and meta-analysis of randomized controlled trials for systemic therapy in AD published during 2007-2018. We searched the Cochrane Library, Medline, Embase, Global Resource for EczemA Trials (GREAT), Literature of the Latin American and Caribbean Health Sciences (LILACS), and Scopus. Two authors performed study selection and data extraction. Multivariable mixed models were constructed for Cohen D of Eczema Area and Severity Index (EASI), SCORing Atopic Dermatitis (SCORAD), numeric rating scale (NRS)–itch and visual analog scale (VAS)–itch, and Dermatology Life Quality Index (DLQI). Overall, 64 trials were included. Use of concomitant topical therapy prescriptions, study duration ≥3 months, and fewer treatment arms were associated with an increased placebo response for EASI, NRS- and VAS-itch, and DLQI. For EASI, the placebo response was increased in studies with a higher proportion of male patients, mild-moderate mean baseline EASI scores, and no blinding. For NRS-itch, and VRS-itch, higher placebo responses were associated with higher proportions of male patients and moderate-severe mean itch scores at baseline. Placebo responses can be reduced in clinical trials of systemic therapy in AD by incorporating double- and triple-blinding, balancing the sex distribution of patients, disallowing concomitant use of prescription topical therapy, and having shorter study durations." @default.
• W2951542229 created "2019-06-27" @default.
• W2951542229 creator A5002975219 @default.
• W2951542229 creator A5007352045 @default.
• W2951542229 creator A5011739266 @default.
• W2951542229 creator A5018781671 @default.
• W2951542229 creator A5030592683 @default.
• W2951542229 creator A5065488200 @default.
• W2951542229 creator A5072653448 @default.
• W2951542229 date "2020-01-01" @default.
• W2951542229 modified "2023-10-11" @default.
• W2951542229 title "Placebo responses in randomized controlled trials for systemic therapy in atopic dermatitis: A systematic review and meta-analysis" @default.
• W2951542229 cites W1504399030 @default.
• W2951542229 cites W1527772966 @default.
• W2951542229 cites W1534948608 @default.
• W2951542229 cites W1947587912 @default.
• W2951542229 cites W1965217362 @default.
• W2951542229 cites W1972335754 @default.
• W2951542229 cites W1972446024 @default.
• W2951542229 cites W1975780852 @default.
• W2951542229 cites W1986025733 @default.
• W2951542229 cites W1997972138 @default.
• W2951542229 cites W2004187951 @default.
• W2951542229 cites W2017891035 @default.
• W2951542229 cites W2022146913 @default.
• W2951542229 cites W2031396947 @default.
• W2951542229 cites W2034280065 @default.
• W2951542229 cites W2043281174 @default.
• W2951542229 cites W2047892076 @default.
• W2951542229 cites W2054312631 @default.
• W2951542229 cites W2056479264 @default.
• W2951542229 cites W2068055137 @default.
• W2951542229 cites W2068331341 @default.
• W2951542229 cites W2084910041 @default.
• W2951542229 cites W2084919926 @default.
• W2951542229 cites W2098146102 @default.
• W2951542229 cites W2117830344 @default.
• W2951542229 cites W2118630839 @default.
• W2951542229 cites W2124615314 @default.
• W2951542229 cites W2134119906 @default.
• W2951542229 cites W2146216258 @default.
• W2951542229 cites W2149187544 @default.
• W2951542229 cites W2168340823 @default.
• W2951542229 cites W2170624839 @default.
• W2951542229 cites W2174132185 @default.
• W2951542229 cites W2174470399 @default.
• W2951542229 cites W2184069226 @default.
• W2951542229 cites W2282788032 @default.
• W2951542229 cites W2321615531 @default.
• W2951542229 cites W2336064636 @default.
• W2951542229 cites W2342994528 @default.
• W2951542229 cites W2419580390 @default.
• W2951542229 cites W2432916178 @default.
• W2951542229 cites W2524051065 @default.
• W2951542229 cites W2593200577 @default.
• W2951542229 cites W2601555940 @default.
• W2951542229 cites W2610814011 @default.
• W2951542229 cites W2753030911 @default.
• W2951542229 cites W2762439354 @default.
• W2951542229 cites W2771011851 @default.
• W2951542229 cites W2783829013 @default.
• W2951542229 cites W2787696154 @default.
• W2951542229 cites W2807789068 @default.
• W2951542229 doi "https://doi.org/10.1016/j.jaad.2019.05.102" @default.
• W2951542229 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31202874" @default.
• W2951542229 hasPublicationYear "2020" @default.
• W2951542229 type Work @default.
• W2951542229 sameAs 2951542229 @default.
• W2951542229 citedByCount "15" @default.
• W2951542229 countsByYear W29515422292020 @default.
• W2951542229 countsByYear W29515422292021 @default.
• W2951542229 countsByYear W29515422292022 @default.
• W2951542229 countsByYear W29515422292023 @default.
• W2951542229 crossrefType "journal-article" @default.
• W2951542229 hasAuthorship W2951542229A5002975219 @default.
• W2951542229 hasAuthorship W2951542229A5007352045 @default.
• W2951542229 hasAuthorship W2951542229A5011739266 @default.
• W2951542229 hasAuthorship W2951542229A5018781671 @default.
• W2951542229 hasAuthorship W2951542229A5030592683 @default.
• W2951542229 hasAuthorship W2951542229A5065488200 @default.
• W2951542229 hasAuthorship W2951542229A5072653448 @default.
• W2951542229 hasConcept C126322002 @default.
• W2951542229 hasConcept C142724271 @default.
• W2951542229 hasConcept C16005928 @default.
• W2951542229 hasConcept C168563851 @default.
• W2951542229 hasConcept C1862650 @default.
• W2951542229 hasConcept C204787440 @default.
• W2951542229 hasConcept C27081682 @default.
• W2951542229 hasConcept C2771230 @default.
• W2951542229 hasConcept C2776173921 @default.
• W2951542229 hasConcept C2778329239 @default.
• W2951542229 hasConcept C2779134260 @default.
• W2951542229 hasConcept C2780501606 @default.
• W2951542229 hasConcept C2780699399 @default.
• W2951542229 hasConcept C535046627 @default.
• W2951542229 hasConcept C71924100 @default.
• W2951542229 hasConcept C95190672 @default.
• W2951542229 hasConceptScore W2951542229C126322002 @default.

• next